Promoter holding
64.27%
SL
Sainor Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Sainorlifesciences: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Sainorlifesciences — 360° Intelligence Report
Generated from MCA filings & public records54/100
Trust Score
Moderate
Sainorlifesciences is assessed as Moderate with a Trust Score of 54/100. Sainorlifesciences is an active private limited indian non-government company incorporated in 2007, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.
Report generated on 13 Jun 2026 from the latest processed filings. Sainor Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
54/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
28/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
30/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 30/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 38%).
- Profitable - internal accruals available.
Charges position: 3 open (26.19 cr) · 2 satisfied (36.92 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 2 | 48.0 cr |
| Others | 2 | 48.0 cr |
| Sidbi | 1 | 48.0 cr |
Compliance Score: 28/100 Caution Indicated
- Company status is Active as per MCA.
- Last balance sheet is for Mar 2022 - filings overdue.
- Flagged by authority: EPFO.
- Litigation present in 1 court forum(s).
- 2 auditor resignation(s) filed - latest: Ratnam Dhaveji & Co on 2023-07-23.
Legal cases on record (1)
05
Director Intelligence
Stability score: 55/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAJESWARA RAO HANUMANTHU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATA SRINIVASA RAO SURA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SIVA BALA BRAHMA REDDY BHEEMAVARAPU KOTIREDDY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KALAGARA SRIDEVI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRABHAKAR RAO GUTHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- RAJESWARA RAO HANUMANTHU has DIN status "Disqualified by RoC u/s 164(2)".
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 7 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Beynon Pharma Private Limited | Associate Company | 74.00% |
Key managerial personnel: KALAGARA SRIDEVI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 45 · Distress 65
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 19+ years.
Active EPFO - real payroll on record.
Distress signals & risk flags
Revenue declined year-on-year.
Statutory filings appear overdue.
Compliance score is weak (28/100).
3 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence47/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment37/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 26.19 cr already registered.
- Compliance gaps should be priced into terms.
Investor view51/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2022
Last AGM held
Annual general meeting
31 Mar 2022
Latest balance sheet
Filed with ROC
10 Dec 2021
Charge created
Others - 4.95 cr
29 Jun 2021
Director ceased
NAGIREDDY DATTATREYA
23 May 2019
Charge created
Sidbi - 2.00 cr
31 Mar 2019
Share transfer (FY 2019)
800000.00000000 shares to RAO RAJESWARA HANUMANTHU
01 Mar 2019
Director appointed
PRABHAKAR RAO GUTHA (Additional Director)
30 Jul 2018
Director ceased
KIRANKUMAR RAMPALLY
31 Mar 2018
Share transfer (FY 2018)
596000.00000000 shares to PRABHAKARA G RAO
05 Sep 2017
Director ceased
SRI SRUJALA SRINIVASA RAO
Director ceased
SRIDURGAPRATHYUSHAA SURA
31 Mar 2017
Share transfer (FY 2017)
320000.00000000 shares to Mani Jayadeva
Share transfer (FY 2017)
269000.00000000 shares to KOTIREDDY SIVA BALA BRAHMA REDDY
Share transfer (FY 2017)
428500.00000000 shares to KOTIREDDY SIVA BALA BRAHMA REDDY
Share transfer (FY 2017)
690000.00000000 shares to ANJAAN
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
5 active director(s) / partner(s); review board churn before relying on management continuity.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Sharma Contractors Private Limited | U45500PB2018PTC047776 | Amritsar, Punjab, India |
| N.M.R Phyrochem Private Limited | U24304HR2017PTC070075 | Panipat, Haryana, India |
| Synergist Bio Private Limited | U24100DL2010PTC202866 | New Delhi, Delhi, India |
| Meenakshi Medical Distributors Private Limited | U74900TN2011PTC081519 | Ambattur, Tamil Nadu, India |
| Basic Pharma Life Science Private Limited | U24230GJ2005PTC046278 | Bharuch, Gujarat, India |
| Apex Pharmachem Private Limited | U24231GJ2001PTC039424 | Vapi, Gujarat, India |
| Paras Oxide Private Limited | U51109UP1990PTC011614 | Muzaffar Nagar, Uttar Pradesh, India |
| Leather Chemicals | L74999HR1985PLC019905 | Haryana, Haryana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sainorlifesciences before audits and certifications: compliance score 28/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sainorlifesciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Sainorlifesciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 54/100, distress signals and MSME payment-delay disclosures - know whether Sainorlifesciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Sainorlifesciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sainorlifesciences an active company?
Sainorlifesciences has MCA status “Active” with a compliance score of 28/100 (Caution Indicated).
Is Sainorlifesciences financially healthy?
Sainorlifesciences has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.
Should I do business with Sainorlifesciences?
Its overall Trust Score is 54/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sainorlifesciences?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.
Does Sainorlifesciences have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Sainorlifesciences up to date with its ROC filings?
Last balance sheet is for Mar 2022 - filings overdue. Overall compliance score: 28/100 (Caution Indicated).
Is it risky to lend to Sainorlifesciences?
Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
